Prior to 2020
Establishing the base
Setting the scene
Launch
HAVING FINALISED pre-clinical studies for PN6047, current focus is on taking this lead compound through regulatory toxicology and first in man trials. Our aim is to establish efficacy through Phase IIA PoC studies in one or more patient populations starting in 2023.
